These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21531600)

  • 1. Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor.
    Makimura H; Stanley TL; Chen CY; Branch KL; Grinspoon SK
    Growth Horm IGF Res; 2011 Jun; 21(3):155-9. PubMed ID: 21531600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.
    Stanley TL; Chen CY; Branch KL; Makimura H; Grinspoon SK
    J Clin Endocrinol Metab; 2011 Jan; 96(1):150-8. PubMed ID: 20943777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
    Ionescu M; Frohman LA
    J Clin Endocrinol Metab; 2006 Dec; 91(12):4792-7. PubMed ID: 17018654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous 24-hour intravenous infusion of recombinant human growth hormone (GH)-releasing hormone-(1-44)-amide augments pulsatile, entropic, and daily rhythmic GH secretion in postmenopausal women equally in the estrogen-withdrawn and estrogen-supplemented states.
    Evans WS; Anderson SM; Hull LT; Azimi PP; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):700-12. PubMed ID: 11158034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unequal impact of age, percentage body fat, and serum testosterone concentrations on the somatotrophic, IGF-I, and IGF-binding protein responses to a three-day intravenous growth hormone-releasing hormone pulsatile infusion in men.
    Iranmanesh A; South S; Liem AY; Clemmons D; Thorner MO; Weltman A; Veldhuis JD
    Eur J Endocrinol; 1998 Jul; 139(1):59-71. PubMed ID: 9703380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
    Makimura H; Murphy CA; Feldpausch MN; Grinspoon SK
    J Clin Endocrinol Metab; 2014 Jan; 99(1):338-43. PubMed ID: 24178787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
    Makimura H; Feldpausch MN; Rope AM; Hemphill LC; Torriani M; Lee H; Grinspoon SK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4769-79. PubMed ID: 23015655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of estradiol supplementation on dual peptidyl drive of GH secretion in postmenopausal women.
    Veldhuis JD; Evans WS; Bowers CY
    J Clin Endocrinol Metab; 2002 Feb; 87(2):859-66. PubMed ID: 11836333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.
    Veldhuis JD; Keenan DM; Bailey JN; Adeniji AM; Miles JM; Bowers CY
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2137-43. PubMed ID: 19351723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P; Isidro ML; Garcia-Buela J; Leal-Cerro A; Broglio F; Tassone F; Ghigo E; Dieguez C; Casanueva FF; Cordido F
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.
    Stanley TL; Feldpausch MN; Murphy CA; Grinspoon SK; Makimura H
    Growth Horm IGF Res; 2014 Feb; 24(1):10-5. PubMed ID: 24291224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum insulin but not leptin is associated with spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in normal volunteers with and without weight loss.
    Manglik S; Cobanov B; Flores G; Nadjafi R; Tayek JA
    Metabolism; 1998 Sep; 47(9):1127-33. PubMed ID: 9751243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
    Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
    J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term modulation of the androgen milieu alters pulsatile, but not exercise- or growth hormone (GH)-releasing hormone-stimulated GH secretion in healthy men: impact of gonadal steroid and GH secretory changes on metabolic outcomes.
    Fryburg DA; Weltman A; Jahn LA; Weltman JY; Samojlik E; Hintz RL; Veldhuis JD
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3710-9. PubMed ID: 9360530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridostigmine treatment selectively amplifies the mass of GH secreted per burst without altering GH burst frequency, half-life, basal GH secretion or the orderliness of GH release.
    Friend K; Iranmanesh A; Login IS; Veldhuis JD
    Eur J Endocrinol; 1997 Oct; 137(4):377-86. PubMed ID: 9368506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG; Macfarlane P; Levitt NS; Millar RP
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
    Bowers CY; Granda-Ayala R
    Endocrine; 2001 Feb; 14(1):79-86. PubMed ID: 11322505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.